These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8609738)

  • 1. Synergistic action of alkylating agents and methylxanthine derivatives in the treatment of chronic lymphocytic leukemia.
    Binet JL; Mentz F; Leblond V; Merle-Beral H
    Leukemia; 1995 Dec; 9(12):2159-61. PubMed ID: 8609738
    [No Abstract]   [Full Text] [Related]  

  • 2. [In vitro induction of apoptosis in chronic lymphoid leukemia B lymphocytes by theophylline: therapeutic applications].
    Binet JL; Mentz F; Baudet S; Ouaaz F; Merle-Béral H
    Bull Acad Natl Med; 1995 Oct; 179(7):1379-91; discussion 1391-2. PubMed ID: 8556412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.
    Jaksic B; Brugiatelli M; Krc I; Losonczi H; Holowiecki J; Planinc-Peraica A; Kusec R; Morabito F; Iacopino P; Lutz D
    Cancer; 1997 Jun; 79(11):2107-14. PubMed ID: 9179056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?
    Ahmadi T; Schuster SJ
    J Clin Oncol; 2009 Feb; 27(4):479-80. PubMed ID: 19075263
    [No Abstract]   [Full Text] [Related]  

  • 6. In defence of the use of modern chemotherapy regimens for the treatment of patients with chronic lymphocytic leukaemia.
    Tam CS
    Intern Med J; 2009 Dec; 39(12):858-9. PubMed ID: 20233254
    [No Abstract]   [Full Text] [Related]  

  • 7. Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders.
    Byrd JC; Grever MR; Waselenko JK; Willis CR; Park K; Goodrich A; Lucas MA; Shinn C; Flinn IW
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):37-40. PubMed ID: 10877050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Specific palatal infiltration in B-cell chronic lymphocytic leukemia].
    Cervigón I; Palomo A; Torres-Iglesias LM; Solano F; Zapata AM
    Actas Dermosifiliogr; 2011 May; 102(4):305-7. PubMed ID: 21354544
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination therapy with nucleoside analogs and alkylating agents.
    Johnston JB; Verburg L; Shore T; Williams M; Israels LG; Begleiter A
    Leukemia; 1994 Apr; 8 Suppl 1():S140-3. PubMed ID: 8152282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.
    Dighiero G; Maloum K; Desablens B; Cazin B; Navarro M; Leblay R; Leporrier M; Jaubert J; Lepeu G; Dreyfus B; Binet JL; Travade P
    N Engl J Med; 1998 May; 338(21):1506-14. PubMed ID: 9593789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance mechanisms in chronic lymphocytic leukemia.
    Ribrag V; Massade L; Faussat AM; Dreyfus F; Bayle C; Gouyette A; Marie JP
    Leukemia; 1996 Dec; 10(12):1944-9. PubMed ID: 8946935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary acute leukemia in chronic lymphocytic leukemia.
    Grünwald HW; Rosner F
    N Engl J Med; 1998 Sep; 339(13):924. PubMed ID: 9750094
    [No Abstract]   [Full Text] [Related]  

  • 14. A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.
    Hebb J; Assouline S; Rousseau C; Desjardins P; Caplan S; Egorin MJ; Amrein L; Aloyz R; Panasci L
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):643-51. PubMed ID: 21120481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA repair and cellular resistance to alkylating agents in chronic lymphocytic leukemia.
    Müller MR; Buschfort C; Thomale J; Lensing C; Rajewsky MF; Seeber S
    Clin Cancer Res; 1997 Nov; 3(11):2055-61. PubMed ID: 9815597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards improved frontline treatment of CLL in the elderly.
    Goede V; Hallek M
    Lancet; 2015 May; 385(9980):1814-5. PubMed ID: 25882395
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil.
    Robak T; Blonski JZ; Kasznicki M; Góra-Tybor J; Dmoszyñska A; Skotñicki A
    Haematologica; 2005 Jul; 90(7):994-6. PubMed ID: 15996945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.
    Robak T; Kasznicki M
    Leukemia; 2002 Jun; 16(6):1015-27. PubMed ID: 12040433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia.
    Goede V; Eichhorst B; Fischer K; Wendtner CM; Hallek M
    Leuk Lymphoma; 2015 Jun; 56(6):1585-92. PubMed ID: 25219593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia.
    Kost SE; Bouchard ED; LaBossière É; Ye X; Queau ML; Liang WS; Banerji V; Gibson SB; Katyal S; Johnston JB
    Leuk Res; 2016 Nov; 50():63-71. PubMed ID: 27683974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.